Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

Rhea-AI Summary

Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), a late-stage pharmaceutical company focusing on central nervous system (CNS), inflammatory, and cardiometabolic diseases, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will engage in a fireside chat during the event.

The virtual summit is scheduled for October 15-17, 2024, with Reviva's fireside chat taking place on Tuesday, October 15, 2024, at 3:30 p.m. ET. Interested parties can access the event through a provided registration link. This participation underscores Reviva's commitment to engaging with the healthcare investment community and showcasing its progress in developing therapies for unmet medical needs.

News Market Reaction – RVPH

-3.31%

-3.31% Session move

In the trading session that priced this news, RVPH declined 3.31%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CUPERTINO, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit, taking place virtually October 15-17, 2024.

2024 Maxim Healthcare Virtual Summit
Format: Fireside chat
Date: Tuesday, October 15, 2024
Time: 3:30 p.m. ET
Location: Virtual
Registration Link: Click Here

About Reviva 
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD 
www.revivapharma.com

Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com

FAQ

When is Reviva Pharmaceuticals (RVPH) participating in the 2024 Maxim Healthcare Virtual Summit?

Reviva Pharmaceuticals (RVPH) is participating in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024, at 3:30 p.m. ET.

Who will represent Reviva Pharmaceuticals (RVPH) at the 2024 Maxim Healthcare Virtual Summit?

Laxminarayan Bhat, Ph.D., the Founder, President, and CEO of Reviva Pharmaceuticals, will represent the company in a fireside chat at the 2024 Maxim Healthcare Virtual Summit.

What is the format of Reviva Pharmaceuticals' (RVPH) participation in the 2024 Maxim Healthcare Virtual Summit?

Reviva Pharmaceuticals (RVPH) will participate in a fireside chat format at the 2024 Maxim Healthcare Virtual Summit.

What are the main areas of focus for Reviva Pharmaceuticals (RVPH) in drug development?

Reviva Pharmaceuticals (RVPH) focuses on developing therapies for unmet medical needs in the areas of central nervous system (CNS), inflammatory, and cardiometabolic diseases.